Relationship Between Specific Autoantibodies Against Platelet Glycoprotein (GPⅡb/Ⅲa And GPIbα) And Clinical Therapeutic Effect (IVIG And Glucocorticosteroid) In Idiopathic Thrombocytopenic Purpura

Objective To evaluate the clinical significance of the relationship between specific autoantibodies against platelet glycoprotein (GPⅡb/Ⅲa and GPIbα) and clinical therapeutic effect(IVIG and glucocorticosteroid) in idiopathic thrombocytopenic purpura .Methods Specific autoantibodies against platelet glycoprotein were measured by a monoclonal antibody immobilization of platelet antigen assay(MAIPA).Results We found that 23%(25/107) of patients had mono-specific antibodies to GPIIb/IIIa and 18%(19/107) had mono-specific antibodies to GPIbα. Another 34%(36/107)of the patients had antibodies to both antigens and 25%(27/107) of patients had no detectable antibody to either platelet antigen. We found that the frequency of catabatic cases in patients with antibodies to both antigens (14/36) was significantly lower than that in patients with mono-specific antibodies to GPIIb/IIIa (23/25) (χ~2=17.439,P<0.01) in ITP. No significant difference was observed between patients with antibodies to both antigens and patients had mono-specific antibodies to GPIbα.(χ~2=0.995,P>0.05)。The clinical therapeutic effect(IVIG and glucocorticosteroid) in patients with mono-specific antibodies to GPIIb/IIIa, antibodies to both antigens and no detectable antibody to either platelet antigen are not so different(P>0.05). Conclusions The kinds of the specific autoantibodies against platelet glycoprotein might be related with clinical therapeutic effect in ITP. The autoantibodies would play a significant role in selecting effective treatment. Typing on the autoantibodies for ITP is insufficiency, need to expand the sample size for further study.